--- title: "Berobenatide | PepTracker Pro" description: "A once-monthly injectable GLP-1 receptor agonist developed by Pfizer (acquired from Metsera), showing 12.3% placebo-adjusted weight loss in Phase 2b trials with a tolerability profile comparable to weekly semaglutide." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Berobenatide", "description": "A once-monthly injectable GLP-1 receptor agonist developed by Pfizer (acquired from Metsera), showing 12.3% placebo-adjusted weight loss in Phase 2b trials with a tolerability profile comparable to weekly semaglutide.", "url": "https://peptrackerpro.com/peptides/berobenatide", "lastReviewed": "2026-06-08", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Berobenatide", "item": "https://peptrackerpro.com/peptides/berobenatide" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People researching once-monthly GLP-1 alternatives to weekly injections?", "acceptedAnswer": { "@type": "Answer", "text": "Berobenatide is a research peptide studied in preclinical models. A once-monthly injectable GLP-1 receptor agonist developed by Pfizer (acquired from Metsera), showing 12.3% placebo-adjusted weight loss in Phase 2b trials with a tolerability profile comparable to weekly semaglutide." } }, { "@type": "Question", "name": "Those evaluating next-generation obesity drug pipeline?", "acceptedAnswer": { "@type": "Answer", "text": "Berobenatide is a research peptide studied in preclinical models. A once-monthly injectable GLP-1 receptor agonist developed by Pfizer (acquired from Metsera), showing 12.3% placebo-adjusted weight loss in Phase 2b trials with a tolerability profile comparable to weekly semaglutide." } }, { "@type": "Question", "name": "Patients and providers interested in reduced injection frequency?", "acceptedAnswer": { "@type": "Answer", "text": "Berobenatide is a research peptide studied in preclinical models. A once-monthly injectable GLP-1 receptor agonist developed by Pfizer (acquired from Metsera), showing 12.3% placebo-adjusted weight loss in Phase 2b trials with a tolerability profile comparable to weekly semaglutide." } }, { "@type": "Question", "name": "Healthcare payers and policy researchers tracking obesity drug pipeline costs?", "acceptedAnswer": { "@type": "Answer", "text": "Berobenatide is a research peptide studied in preclinical models. A once-monthly injectable GLP-1 receptor agonist developed by Pfizer (acquired from Metsera), showing 12.3% placebo-adjusted weight loss in Phase 2b trials with a tolerability profile comparable to weekly semaglutide." } } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Peptides](/peptides)/ Berobenatide **Research-only content.** This page is for educational purposes and does not constitute medical advice. [Read full disclaimer →](/research-disclaimer) # Berobenatide Medium Evidence A once-monthly injectable GLP-1 receptor agonist developed by Pfizer (acquired from Metsera), showing 12.3% placebo-adjusted weight loss in Phase 2b trials with a tolerability profile comparable to weekly semaglutide. Aliases MET-097 +1 more Evidence Medium Evidence Last Updated 2026-06-08 Reading Time 3 min ## Table of Contents 1. [What It Is](#what-it-is) 2. [Regulatory Status](#regulatory-status) 3. [Why Researchers Study It](#why-researchers-study) 4. [Proposed Mechanisms](#proposed-mechanisms) 5. [Evidence Snapshot](#evidence-snapshot) 6. [Commonly Discussed Benefits](#benefits) 7. [Safety & Cautions](#safety) 8. [Comparisons](#comparisons) 9. [Calculator Tools](#calculator) 10. [Citations](#citations) ## What It Is Berobenatide is an investigational long-acting injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) originally developed by Metsera and acquired by Pfizer in November 2025 for approximately $7 billion. Its key differentiator is dosing interval: berobenatide is designed for once-monthly subcutaneous injection, compared with the once-weekly standard for semaglutide (Wegovy) and tirzepatide (Zepbound). The extended half-life is achieved through Metsera's proprietary fatty acid conjugation and half-life extension technology. Phase 2b VESPER-3 trial data presented at ADA 2026 (June 5-8, New Orleans) showed placebo-adjusted weight loss of up to 12.3% at 28 weeks with the 4.8 mg monthly dose in adults with obesity without type 2 diabetes, with no evidence of weight loss plateau at week 28. In a 32-week exploratory extension, participants who escalated from placebo to 2.4 mg weekly berobenatide achieved a non-placebo-adjusted weight loss of 15.9%, suggesting further efficacy at longer durations. For type 2 diabetes, Phase 2b VESPER-1 data presented at ADA 2026 showed up to 10.2% weight loss alongside a 2.2 percentage-point reduction in blood glucose at 28 weeks in adults with obesity and T2D. The gastrointestinal tolerability profile was comparable to weekly Wegovy: 83% of treated participants reported no or only mild key gastrointestinal adverse events, with GI events largely clustered near dose administration and decreasing over time. Pfizer announced plans to initiate 10 Phase 3 studies for berobenatide in 2026, targeting chronic weight management and obesity-related comorbidities including knee osteoarthritis and obstructive sleep apnea. Also known as: MET-097, Metsera GLP-1 ## Regulatory Status Investigational Phase 2b data presented at ADA 2026 (June 2026). Pfizer plans to initiate 10 Phase 3 trials in 2026 for weight management and obesity comorbidities. No FDA submission yet. Effective: June 2026 [View FDA Source](https://www.businesswire.com/news/home/20260605120877/en/Robust-Phase-2b-Efficacy-and-Favorable-Tolerability-Support-Monthly-Dosing-for-Pfizers-GLP-1-RA-Berobenatide) ## Why Researchers Study It Berobenatide is the most advanced once-monthly GLP-1 RA in clinical development. Monthly dosing could significantly expand patient adherence compared with weekly injectables, particularly in populations where weekly injection burden drives discontinuation. If Phase 3 results confirm Phase 2b efficacy and tolerability, berobenatide would be the first monthly GLP-1 RA on the market — potentially reshaping the obesity drug landscape. ## Proposed Mechanisms - GLP-1 receptor agonism reduces appetite and food intake via hypothalamic signaling - Slows gastric emptying to prolong post-meal satiety - Stimulates glucose-dependent insulin secretion from pancreatic beta cells - Fatty acid conjugation extends half-life to enable monthly dosing without loss of receptor engagement - Sustained receptor activation from once-monthly injection may reduce peak-trough GI side effect cycles ## Evidence Snapshot Medium Evidence Low Medium High Study Type Model Outcome Link Human (Phase 2b, VESPER-3) Adults with obesity without T2D, monthly dosing arms, 28 weeks 12.3% placebo-adjusted weight loss at 4.8 mg monthly dose; no plateau at week 28 [Source](https://www.businesswire.com/news/home/20260605120877/en/Robust-Phase-2b-Efficacy-and-Favorable-Tolerability-Support-Monthly-Dosing-for-Pfizers-GLP-1-RA-Berobenatide) Human (Phase 2b, VESPER-3 extension) Participants escalated from placebo to 2.4 mg weekly, 32 weeks 15.9% non-placebo-adjusted weight loss at 32 weeks; weight loss continuing without plateau [Source](https://www.statnews.com/2026/06/06/pfizer-obesity-drug-berobenatide-metsera-results/) Human (Phase 2b, VESPER-1) Adults with obesity and type 2 diabetes, 28 weeks 10.2% weight loss + 2.2 percentage-point blood glucose reduction; consistent GLP-1 RA safety profile [Source](https://endpoints.news/ada26-pfizer-monthly-shot-shows-effect-on-obesity-diabetes/) ## Commonly Discussed Benefits [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) Researching Berobenatide ? Track it, set reminders, and keep notes in the free app. [Track in App](https://app.peptrackerpro.com/?add=berobenatide) ## Safety & Cautions - Phase 3 trials not yet initiated as of June 2026 - Weight loss at 12.3% is lower than leading weekly injectables (semaglutide 2.4 mg: ~15%, tirzepatide 15 mg: ~22%) — though longer duration and higher doses may close the gap - Monthly dosing means missed injections could lead to longer gaps in drug coverage than with weekly agents - Long-term safety data beyond 32 weeks is not yet available - Not FDA-approved for any indication ## Comparisons See how Berobenatide compares to related peptides: [Berobenatide vs Danuglipron](/compare/berobenatide-vs-danuglipron) [Berobenatide vs Orforglipron](/compare/berobenatide-vs-orforglipron) [Berobenatide vs Retatrutide](/compare/berobenatide-vs-retatrutide) [Berobenatide vs Semaglutide](/compare/berobenatide-vs-semaglutide) [Berobenatide vs Tirzepatide](/compare/berobenatide-vs-tirzepatide) ## Calculator Tools Use our research tools to explore dosing and reconstitution data: [Reconstitution Calculator](/calculators) ## Citations 1. \[1\] Pfizer — Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Berobenatide (ADA 2026) [PubMed](https://www.businesswire.com/news/home/20260605120877/en/Robust-Phase-2b-Efficacy-and-Favorable-Tolerability-Support-Monthly-Dosing-for-Pfizers-GLP-1-RA-Berobenatide) 2. \[2\] STAT News — Detailed data show Pfizer's monthly obesity drug continues to show potential (June 2026) [PubMed](https://www.statnews.com/2026/06/06/pfizer-obesity-drug-berobenatide-metsera-results/) 3. \[3\] Fierce Biotech — ADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buy [PubMed](https://www.fiercebiotech.com/biotech/ada-pfizer-pads-case-berobenatide-obesity-adding-validation-metsera-buy) 4. \[4\] Endpoints News — ADA26: Pfizer monthly shot shows effect on obesity, diabetes [PubMed](https://endpoints.news/ada26-pfizer-monthly-shot-shows-effect-on-obesity-diabetes/) ### Keep researching in the app - Log Berobenatide to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack [Open PepTracker Pro Free](https://app.peptrackerpro.com/?add=berobenatide) [Browse more peptides](/peptides) ## Related Peptides ### Danuglipron Medium Evidence An oral small-molecule GLP-1 receptor agonist discontinued by Pfizer in 2026 after a potential drug-induced liver injury signal, despite showing meaningful weight loss in Phase 2b. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism) [View Details](/peptides/danuglipron) [\+ Compare](/compare?select=danuglipron)[](https://app.peptrackerpro.com/?add=danuglipron) ### Orforglipron High Evidence The first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/orforglipron) [\+ Compare](/compare?select=orforglipron)[](https://app.peptrackerpro.com/?add=orforglipron) ### Retatrutide High Evidence An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/retatrutide) [\+ Compare](/compare?select=retatrutide)[](https://app.peptrackerpro.com/?add=retatrutide) ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+3 more [View Details](/peptides/semaglutide) [\+ Compare](/compare?select=semaglutide)[](https://app.peptrackerpro.com/?add=semaglutide) ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/tirzepatide) [\+ Compare](/compare?select=tirzepatide)[](https://app.peptrackerpro.com/?add=tirzepatide) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.